This work reports the development of a gallium nitride-based high electronic mobility
transistor (GaN HEMT)-based biosensor to detect human epidermal growth factor receptor-2 …

Background HER2 (or ERBB2) amplification is an important mechanism for acquired
resistance to EGFR tyrosine kinase inhibitors (TKI). The benefits of HER2-targeted therapy …

The significant clinical benefits of human epidermal growth factor receptor 2 (HER2)‐
targeted therapeutic agents have revolutionized the clinical treatment landscape in a variety …

Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has
raised global concern. Although several papers have reviewed the current state of ADCs in …

Objective Besides breast and gastric cancer, HER2 amplification/mutation are also found in
lung adenocarcinoma (LUAD). However, the correlation between HER2 variations and the …

Background Invasive mucinous adenocarcinoma (IMA) of the lung is a rare and distinct
subtype of adenocarcinoma. At present, people have no idea whether IMA patients can …

Among the lung cancers, approximately 85% are histologically classified as non-small-cell
lung cancer (NSCLC), a leading cause of cancer deaths worldwide. Epidermal growth factor …

Background Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the
era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and …

Introduction The KRAS (G12C) mutation is the most common genetic mutation in North
American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C …

Simple Summary Non-small-cell lung cancer (NSCLC) remains one of the most common
tumors with a high mortality and morbidity rate. Alterations in HER2 and MET could be a …